Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

11/12/24 10:32:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IDYA alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 IDEAYA BIOSCIENCES COMMON STOCK Cusip #45166A102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #45166A102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 12,633,054 Item 6: 0 Item 7: 12,635,652 Item 8: 0 Item 9: 12,635,652 Item 11: 14.956% Item 12: HC Cusip #45166A102 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 12,635,652 Item 8: 0 Item 9: 12,635,652 Item 11: 14.956% Item 12: IN Item 1(a). Name of Issuer: IDEAYA BIOSCIENCES Item 1(b). Address of Issuer's Principal Executive Offices: 7000 SHORELINE COURT, SUITE 350 SOUTH SAN FRANCISCO, CA 94080 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 45166A102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 12,635,652 (b) Percent of Class: 14.956% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 12,635,652 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of IDEAYA BIOSCIENCES. The interest of Fidelity Growth Company Commingled Pool, in the COMMON STOCK of IDEAYA BIOSCIENCES, amounted to 5,411,635 shares or 6.405% of the total outstanding COMMON STOCK at September 30, 2024. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company * BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of IDEAYA BIOSCIENCES at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $IDYA alert in real time by email

Recent Analyst Ratings for

$IDYA

Date	Price Target	Rating	Analyst
9/4/2025	$40.00	Overweight	Barclays
9/4/2025	$41.00	Mkt Outperform	Citizens JMP
7/22/2025		Buy	TD Cowen
7/10/2025	$25.00	Neutral	Goldman
6/26/2025	$44.00	Overweight	Wells Fargo
11/18/2024	$51.00	Overweight	Stephens
11/5/2024	$27.00	Outperform → Market Perform	Leerink Partners
10/24/2024	$50.00	Buy	UBS

More analyst ratings

Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

11/12/24 10:32:13 AM ET

$IDYA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IDYA alert in real time by email

Recent Analyst Ratings for

$IDYA

Date	Price Target	Rating	Analyst
9/4/2025	$40.00	Overweight	Barclays
9/4/2025	$41.00	Mkt Outperform	Citizens JMP
7/22/2025		Buy	TD Cowen
7/10/2025	$25.00	Neutral	Goldman
6/26/2025	$44.00	Overweight	Wells Fargo
11/18/2024	$51.00	Overweight	Stephens
11/5/2024	$27.00	Outperform → Market Perform	Leerink Partners
10/24/2024	$50.00	Buy	UBS

More analyst ratings

Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$IDYA

Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$IDYA

$IDYA
Analyst Ratings

Barclays initiated coverage on IDEAYA Biosciences with a new price target

Citizens JMP initiated coverage on IDEAYA Biosciences with a new price target

TD Cowen initiated coverage on IDEAYA Biosciences

$IDYA
SEC Filings

SEC Form 8-K filed by IDEAYA Biosciences Inc.

SEC Form 8-K filed by IDEAYA Biosciences Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by IDEAYA Biosciences Inc.

$IDYA
Press Releases

$IDYA
Insider Trading

Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma

SEC Form 3 filed by new insider Bleharski Joshua

SEC Form 4 filed by Director Yarno Wendy L

SEC Form 4 filed by Director Stein Jeffrey

$IDYA
Leadership Updates

IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

$IDYA
Financials

IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

$IDYA
Large Ownership Changes